Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 27;16:867–883. doi: 10.2147/OTT.S429128

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Therapeutic efficacy of B7 against subcutaneous CT26 tumors in vivo. (A) Morphological observation of the mouse CRC tumor tissue of different groups. (B) The tumor growth curves of CT26 tumor-bearing mice. (C) The body weight changes of mice were recorded. (D) H&E staining of main organs of mice. The data are represented as the mean ± SD (n = 3). (E) Immunohistochemical staining of Ki-67 in tumor tissue. (F) TUNEL analysis of H tumor tissue treated with B7 (scale bar = 100 µm). And associated (G) statistical analysis of TUNEL fluorescence signal intensity. Statistical differences were considered significant at * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.